- Home
- JMM vs IMA Comparison
JMM vs IMA Comparison
Compare JMM & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMM | IMA |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.8M | 54.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JMM | IMA |
|---|---|---|
| Price | $5.87 | $5.70 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 5.4K | ★ 380.5K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.70 | $3.94 |
| 52 Week High | $6.52 | $17.50 |
Technical Indicators
Market Signals| Indicator | JMM | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 51.37 |
| Support Level | $5.73 | $5.52 |
| Resistance Level | $5.94 | $7.04 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 23.53 | 40.42 |
Price Performance
Historical ComparisonAbout JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.